Overall, our NMA comprehensively compared the efficacy and safety of PD‐1 inhibitors + chemotherapy and PD‐L1 inhibitors + chemotherapy in the first‐line therapy of patients with ES‐SCLC and found no statistically significant differences in terms of OS, PFS, ORR, and AEs in ES‐SCLC based on the limited data available. The gene discussed is CD274; the disease is small cell lung carcinoma.